Latest information on COVID-19
Support teaching, research, and patient care.
Dr Rahul P. Sharma, MBBS, FRACP is the Director of Structural Interventions at Stanford Healthcare and Clinical Assistant Professor of Medicine at Stanford University. Dr Sharma graduated from Monash University and completed his medicine and cardiology training at the Alfred Hospital in Melbourne, Australia. He completed an advanced interventional and structural fellowship at Cedars Sinai Medical Center in Los Angeles, California in 2015 before joining Cedars Sinai as Clinical Faculty, Director of the Structural Imaging Core Laboratory and Associate Director of Interventional Cardiology Research until 2019, before joining Stanford Healthcare. Dr Sharma is an Interventional Cardiologist with specialized clinical and research interests in structural heart disease, particularly transcatheter valve therapy. He has a large volume of expertise in transcatheter aortic, mitral and tricuspid replacement, percutaneous mitral valve repair, left atrial appendage occlusion, PFO/ASD/VSD closure, alcohol septal ablation and cerebral protection. He also has expertise in CT imaging for structural heart disease. He is a clinical investigator in ongoing national multi-center research studies and clinical trials and has co-authored numerous peer reviewed, scientific articles and book chapters. Dr Sharma also serves as a national and international clinical proctor for transcatheter aortic and mitral valve implantation and percutaneous mitral valve repair and speaks regularly at major national and international cardiology meetings.
Transcatheter valve therapies, CT valve imaging, AI and device innovation
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair
System in patients with degenerative mitral regurgitation (DMR) who have been determined to
be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with
functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
View full details
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System
in patients with symptomatic severe tricuspid regurgitation who have been determined to be at
an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the
cardiac surgeon with concurrence by the local Heart Team
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All
subjects enrolled with receive the study device.
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with three trial cohorts:
Randomized, Non-Randomized, and Mitral Annular Calcification (MAC). Subjects in the
Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip
system. Subjects in the Non-Randomized and MAC cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the
Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is
to evaluate the safety and effectiveness of the Tendyne Mitral Valve System for the treatment
of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for
patients with symptomatic mitral valve disease due to severe mitral annular calcification.
This randomized controlled trial will provide the opportunity to evaluate the safety and
clinical benefits of the Tendyne Mitral Valve System compared to the MitraClip System in
patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved
MitraClip indications. In addition, the safety and effectiveness of the Tendyne Mitral Valve
System will be evaluated in patients with severe mitral annular calcification who are at
prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve
surgery for reasons other than severe mitral annular calcification and are also not suitable
for transcatheter repair with MitraClip, will be enrolled in the Non-randomized cohort.
Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6
months, and annually through 5 years.
ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for
transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis
who are indicated for TAVR.
PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
To establish the safety and effectiveness of the Edwards SAPIEN 3 Transcatheter Heart Valve
in patients with severe, calcific aortic stenosis who are at low operative risk for standard
aortic valve replacement (AVR).